Omair Yousuf, MD
Clinical Cardiac Electrophysiology · Arlington, VANPI 1104083260
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Boston Scientific at 35.8% of the total.
Across 196 payments — averaging $156.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$11K
- Medtronic$7K
- Abbott$5K
- Biosense Webster, Inc.$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Biotronik Inc.$1K
- plus $2K from 20 others
What the payments were for
- Consulting fees$3,26211%
- Speaking & faculty fees$10,80035%
- Travel & lodging$8,31227%
- Food & beverage$8,32527%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 24 | $10,985 |
| Medtronic(2 entities) | 46 | $7,082 |
| Abbott | 42 | $5,423 |
| Biosense Webster, Inc. | 23 | $2,202 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $1,633 |
| Biotronik Inc. | 4 | $1,128 |
| E.r. Squibb & Sons, L.L.C. | 5 | $399 |
| Novartis | 8 | $298 |
| Impulse Dynamics (USA) Inc. | 2 | $280 |
| Johnson & Johnson | 5 | $265 |
| Novo Nordisk | 7 | $246 |
| Atricure, Inc. | 2 | $150 |
| ZOLL Respicardia, Inc. | 1 | $136 |
| Pfizer | 1 | $95 |
| Merck | 4 | $90 |
| Qorumpartners | 1 | $59 |
| AstraZeneca | 2 | $57 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Philips North America LLC | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Coala Life Inc | 1 | $19 |
| Amgen | 1 | $18 |
| Smith+Nephew | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Medicomp Inc | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$7,619
- Ensite Cardiac Mapping System$2,262
- AVEIR$2,006
- Micra$1,800
- Carto 3$1,569
- LifeVest$1,500
- WATCHMAN Access System$1,255
- Watchman$1,118
- EVERA MRI XT DR SURESCAN$547
- CAMZYOS$366
- Viva$226
- OPTIMIZER SMART SYSTEM$188
- AZURE XT DR MRI SURESCAN$147
- ViewFlex Xtra ICE Catheter$139
- remede System$136
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$134
- CLARIA MRI QUAD CRT-D SURESCAN$131
- JOT DX$130
- SelectSecure$130
- ENSITE$129
How this compares
$30,712 in reported general payments places this provider in the 60th percentile of 90 clinical cardiac electrophysiology providers in Virginia.
See all clinical cardiac electrophysiology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 233 | $289,343 |
| EntrestoSacubitril/Valsartan | 75 | $86,069 |
| XareltoRivaroxaban | 86 | $81,239 |
| OzempicSemaglutide | 33 | $40,652 |
| FarxigaDapagliflozin Propanediol | 34 | $35,583 |
| JardianceEmpagliflozin | 24 | $31,390 |
| MultaqDronedarone Hcl | 11 | $15,023 |
| Repatha SureclickEvolocumab | 14 | $13,129 |
| Dofetilide | 57 | $6,321 |
| Flecainide Acetate | 141 | $4,633 |
| Amiodarone Hcl | 58 | $4,349 |
| Metoprolol Succinate | 181 | $2,318 |
| Potassium Chloride | 43 | $1,863 |
| Amlodipine Besylate | 166 | $1,327 |
| Atorvastatin Calcium | 104 | $1,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $95 | $289,343233 claims |
| NovartisEntresto | $298 | $86,06975 claims |
| Johnson & JohnsonXarelto | $265 | $81,23986 claims |
| Novo NordiskOzempic | $246 | $40,65233 claims |
| AstraZenecaFarxiga | $57 | $35,58334 claims |
| Sanofi-aventis U.S. LLCMultaq | $45 | $15,02311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 90 clinical cardiac electrophysiology providers in Virginia.
Other clinical cardiac electrophysiology in Arlington
- Kenneth EllenbogenRichmond$360K
- Brett AtwaterFairfax$319K
- Oliver MonfrediCharlottesville$231K
- Peem LorvidhayaFredericksburg$230K
- Erich KiehlNewport News$181K
- Emmanuel EkanemWinchester$132K
- Pamela MasonCharlottesville$130K
- Ajay PillaiRichmond$129K
- Stephen GaetaFairfax$85K
- Charles JoynerRichmond$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.